PATENT AND TRADEMARK OFFICE  APPLICANT				·.	ATTY DOCKET NO. 00766.000043	APPLICATION NO. 09/749,728		
				APPLICANT Akihiro Umez	skihiro Umezawa, et al.			
(Use several sheets if necessaryAN 1 8 2005					GROUP 10	OUP 1632		
			Max No	<u> </u>	U.S. PATENT DOCUMENTS			
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE
		·	·	•				
		-				<u> </u>		
				•				
						<u> </u>	.   .	
				FO	REIGN PATENT DOCUMENTS	•	· <u> </u>	
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
						ļ		
						ļ., .		
				<del></del>	/	<u> </u>		·.
ļ		· · · · · · · · · · · · · · · · · · ·	OTHER DOCUM	ENT(S	) (Including Author, Title, Date, Pertinent Pages, Etc.)			· · · · · · · · · · · · · · · · · · ·
20	Takeda, et al., "Can the life span of human marrow stromal cells be prolonged", The Journal of Gene Medicine, Vol. 6 (2004), pages 833-845							
10	Xu, et al., "Mesenchymal Stem Cells from Adult Human Bone Marrow Differentiate into a", Society of Experimental Biology and Medicine, Vol. 229 (2004) pages 623-631							
EXAMINER -	70	1 Dalla			DATE CONSIDERED 4/30/0			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	1 1	of.	1

80766.000043

## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	) : Examiner: Ram R. Shuk	Ram R Shukla		
AKIHIRO UMEZAWA, ET AL.	) : Group Art Unit: 1632	ıa		
Application No.: 09/749,728	)			
Filed: December 28, 2000	j			
For: THE CELL HAVING THE POTENTIALITY OF DIFFERENTIATION INTO CARDIOMYOCYTES	) : ) : January 13, 2005	٠.		

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

January 13, 2005 (Date of Deposit)

01/21/2005 YPOLITE1 00000002 09749728

02 FC:1806

180.00 OP

LAWRENCE S. PERRY

and K

January 13, 2005

Date of Signature

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

We also enclose a check for the required fee of \$180.00 to cover the Information Disclosure Statement under 37 C.F.R. 1.97(c)(2).

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

Attorney for Applicants Lawrence S. Perry

Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO 30 Rockefeller Plaza New York, New York 10112-3801 Facsimile: (212) 218-2200

NY MAIN 475794v1

SEP 1 0 2004

00766.000043

#### **PATENT APPLICATION**

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	) Cuaminari Dam D. Shukla
AKIHIRO UMEZAWA, ET AL.	: Examiner: Ram R. Shukla
Application No.: 09/749,728	: Group Art Unit: 1632
Filed: December 28, 2000	)
For: THE CELL HAVING THE POTENTIALITY OF DIFFERENTIATION INTO CARDIOMYOCYTES	) : ) : September 9, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed together with a copy of the Supplementary European Search Report in a counterpart foreign application.

#### STATEMENT UNDER 37 C.F.R. § 1.97(e)

Each item of information in this information disclosure statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Statement.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

Attorney for Applicants

Lawrence S. Perry

Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO 30 Rockefeller Plaza New York, New York 10112-3801 Facsimile: (212) 218-2200

NY MAIN 450867vI

FORM PTO 1449 (mod	•	AEDCC	ATTY DOCKET NO. 00766.000043	APPLICATION NO. 09/749,728			
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE O PE LIST OF REFERENCES CITED BY APPLICANT(S)			APPLICANT				
(0	se several sheets if neces:	SEP 1 0 2004	FILING DATE		ROUP	20	
			December 28, 2000 1632			32	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
		-					
		FC	DREIGN PATENT DOCUMENTS	Т	<del></del>		
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT	
242	WO 00/44882	8/00	· PCT	_			
<i>u</i>				ļ			
				-			
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
7160	Hu, et al., "Transidfferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα", <i>Proc. Natl. Acad. Sci.</i> , Vol. 92, No. 21 (1995), pages 9856-9860						
7W	Rosen, et al., "PPARγ Is Required for the Differentiation of Adipose Tissue <i>In Vivo</i> and <i>In Vitro</i> ", <i>Molecular Cell</i> , Vol. 4, No. 4 (1999), pages 611-617						
EXAMINER	701/2		DATE CONSIDERED 4/30/65				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet\_1\_ of \_1\_